Home › Dilated Cardiomyopathy › NCT06688396
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
RecruitingHealthy volunteers welcome
Dilated Cardiomyopathy Detection Using Artificial Intelligence and Screening With Mobile Technology
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria (Proband) * Male or female age ≥ 18 years * Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient * Must have at least one living adult FDR * Able to provide informed consent Inclusion Criteria (FDR) * Male or female age ≥ 18 years who are first-degree relatives of patients with DCM * Proband has provided informed consent * FDR able to provide informed verbal consent * Access to a smartphone or digital tablet with cellular data or Wi-Fi access Exclusion Criteria (Proband) * DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination * Proband has previously informed FDR to undergo cardiac screening * Ischemic cause of reduced LVEF * evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease * history of acute coronary syndromes (STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-Elevation Myocardial Infarction) or unstable angina) revascularization or ≥75% stenosis of either left main or Left Anterior Descending (LAD) or ≥75% stenosis of 2 major epicardial vessels on angiogram * Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy * Congenital structural heart disease * Severe and untreated or untreatable hypertension * Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload * Any secondary cause of reduced LVEF such as pregnancy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug * (CPC Participants only) Home address outside of traveling range Exclusion Criteria (FDR) * Previously informed about cardiac screening or has completed cardiac screening by transthoracic echocardiogram (TTE) * Previously diagnosed with reduced LVEF * (CPC Participants only) Home address outside of traveling range
About the study
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
What is being tested
- Mobile 6L AI-EKG Screening (device)
Sponsor: Lancaster General Hospital · Participants: 150 · Started: Dec 4, 2024
Contact the study team
- Halle Becker, MPH · Phone: 717-544-1777
- Jonathan Derr, MBA · Phone: 717-544-1777
Official record on ClinicalTrials.gov — NCT06688396
Locations in the U.S.
| Pennsylvania | Lancaster General Hospital, Lancaster |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.